BAY86-5046 (Betaseron), Non Interventional Studies
Launched by BAYER · Apr 22, 2014
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome.
- • Patients must be on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician.
- • Patient and attending physicians must have agreed on the usage of the BETACONNECT auto-injector device
- • Written informed consent must be obtained.
- Exclusion Criteria:
- • Patients receiving any other disease modifying drug.
- • Contraindications of Betaferon described in the Summary of Product Characteristics.
About Bayer
Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Many Locations, , Germany
Patients applied
Trial Officials
Bayer Study Director
Study Director
Bayer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials